Safranal Treatment Improves Hyperglycemia, Hyperlipidemia and Oxidative Stress in Streptozotocin-Induced Diabetic Rats
Safranal Treatment Improves Hyperglycemia, Hyperlipidemia and Oxidative Stress in Streptozotocin-Induced Diabetic Rats
复制标题
DOI：
10.18433/j3zs3q
复制
发表时间：
2013-01-01
影响因子：
2.7
通讯作者：
Samini, Fariborz
中科院分区：
文献类型：
--
作者：
Samarghandian, Saeed;Borji, Abasalt;Samini, Fariborz
目的。临床研究已证实多种植物提取物在调节与糖尿病相关的氧化应激方面的功效。研究结果表明藏花醛具有抗氧化特性。本研究的目的是评估藏花醛对糖尿病大鼠氧化损伤的可能保护作用。方法。在这项研究中，将大鼠分为以下组，每组 8 只动物：对照组、未治疗的糖尿病组、三个藏花醛（0.25、0.50、0.75 mg/kg/天）治疗的糖尿病组。链脲佐菌素（STZ）诱发大鼠糖尿病。 STZ单剂量60mg/kg腹腔注射诱导糖尿病。 STZ给药后3天给予Safranal（腹膜内注射）；这些注射持续到研究结束（4周）。 4周结束时，抽血进行生化检测。为了确定细胞抗氧化防御系统的变化，测量了血清中谷胱甘肽过氧化物酶（GSHPx）、超氧化物歧化酶（SOD）和过氧化氢酶（CAT）等抗氧化酶的活性。此外，我们还测量了血清一氧化氮（NO）和血清丙二醛（MDA）水平，这是脂质过氧化的标志物。结果。 STZ 诱导的糖尿病导致血糖、MDA、NO、总脂、甘油三酯和胆固醇升高 (p < 0.001)，同时 GSH 水平以及 CAT 和 SOD 活性降低。结果表明，与未治疗组相比，藏红花治疗的糖尿病组的血糖、MDA、NO、总脂质、甘油三酯、胆固醇的显着升高以及谷胱甘肽水平以及 CAT 和 SOD 活性的降低均以剂量依赖性方式得到改善（p < 0.05，p
Purpose. Clinical research has confirmed the efficacy of several plant extracts in the modulation of oxidative stress associated with diabetes mellitus. Findings indicate that safranal has antioxidant properties. The aim of the present study was the evaluation of possible protective effects of safranal against oxidative damage in diabetic rats. Methods. In this study, the rats were divided into the following groups of 8 animals each: control, untreated diabetic, three safranal (0.25, 0.50, 0.75 mg/kg/day)-treated diabetic groups. Diabetes was induced by streptozotocin (STZ) in rats. STZ was injected intraperitoneally at a single dose of 60 mg/kg for diabetes induction. Safranal (intraperitoneal injection) was administered 3 days after STZ administration; these injections were continued to the end of the study (4 weeks). At the end of the 4-week period, blood was drawn for biochemical assays. In order to determine the changes of cellular antioxidant defense systems, antioxidant enzymes including glutathione peroxidase (GSHPx), superoxide dismutase (SOD) and catalase (CAT) activities were measured in serum. Moreover we also measured serum nitric oxide (NO) and serum malondialdehyde (MDA) levels, a marker of lipid peroxidation. Results. STZ-induced diabetes caused an elevation (p < 0.001) of blood glucose, MDA, NO, total lipids, triglycerides and cholesterol, with reduction of GSH level and CAT and SOD activities. The results indicated that the significant elevation in the blood glucose, MDA, NO, total lipids, triglycerides, cholesterol and reduction of glutathione level and CAT and SOD activity were ameliorated in the safranal-treated diabetic groups compared with the untreated groups, in a dose dependent manner (p < 0.05, p